< Back to latest news & events

News

Notice from the European Patent Office dated 22 February 2021 concerning the amendment of Rules 19 and 143 EPC

March 2021

From 1 April 2021, inventors will no longer be notified by the EPO about being named in a patent application. In addition, applicants will no longer be required to indicate the full address of the inventor in the application, only the country and place of residence.

Amended Rule 19 (comes into force 1 April 2021):
  • Inventors are no longer notified by the EPO about their designation.
  • Applicants are no longer required to indicate the full address of the inventor only the country, city and post code.
  • Online filing tools will be updated so that they no longer have a dedicated field for entering a full address; nor will there be a dedicated field for “Company” or “Department” for inventors.
Amended Rule 143 (comes into force 1 Nov 2021):
  • Full addresses of inventors are no longer published in the EP patent register – only the country and place of residence.

Rule 20(1) still holds and is unaffected by either amended Rule 19 or Rule 143. An inventor can therefore still waive their right to be mentioned.

Reasons for the Changes:

Read the article here.

The EPO sends letters to notify inventors that they have been named on an application which is a considerable administrative burden (530,194 letters were sent in 2019 costing 307,000 EUR). In addition many of these letters are undeliverable due to incorrect addresses (36,000 in total). Updating online filing tools on the EPO IT systems will cost 50,000 EUR initially but save money in the long run.

Furthermore, due to data protection the EPO feel it is unnecessary to have the whole of the inventor’s address published on the EP patent register and that the name and city of the inventor is sufficient.

If you would like further advice on this or any other matter, please contact your usual HGF attorney or visit our Contact Page to get in touch with your nearest HGF office.

Latest updates

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Precision Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article

Novelty Over Clinical Trials at the EPO

Video overview: Second medical use claims can be novel over clinical trials in European patents.  Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article

Added Matter - Part 2

Video overview: Pre- and Post-Grant Amendments are governed by Articles 123(2) & 123(3) EPC respectively Before grant, amendments can broaden the claim scope as long as the resulting claim is …

Read article

Added Matter - Part 1

Video overview: What is Added Matter? Added matter occurs when an amendment introduces content that goes beyond what was originally disclosed in the application as filed (Article 123(2) EPC). EPO …

Read article